Skip to main content
Clinical Trials/NL-OMON53880
NL-OMON53880
Not yet recruiting
Not Applicable

A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of GATT-Patch Versus TachoSil for Hemostasis During Open Liver Surgery - Safety/efficacy of GATT-Patch vs TachoSil During Open Liver Surgery

GATT Technologies BV0 sites50 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
GATT Technologies BV
Enrollment
50
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subject is scheduled to undergo elective open surgery on the liver;
  • Subject is willing and able to give written informed consent for the clinical
  • investigation participation;
  • Subjects is 22 years of age or older at the time of enrollment; and
  • Subject has been informed of the nature of the clinical investigation.
  • Subject in whom the Investigator is able to identify a target bleeding site
  • at the liver resection plane for which any applicable conventional means for
  • hemostasis (e.g. suture, ligature or cautery) are ineffective or impractical,
  • and the choice is made to use a hemostatic agent to stop the bleeding; and
  • Subject has a target bleeding site with a SBSS of 1, 2, or 3 (e.g. reflecting

Exclusion Criteria

  • The target bleeding site is from a large defect in an artery or vein that
  • requires vascular reconstruction with maintenance of vessel patency;
  • Subject is scheduled to undergo surgery on other organs than the liver and
  • its associated biliary and vascular system;
  • Subject is scheduled to undergo a staged liver surgery procedure (e.g.,
  • Associating Liver Partition and Portal vein ligation for Staged hepatectomy
  • Subject is taking multiple antithrombotic therapies in therapeutic dosage up
  • to the time of surgery, but allowing exclusive use of acetylsalicylic acid;
  • Subject has platelet count \<100 x 109/L, an activated partial thrombin time
  • of \>100s, or international normalized ratio \>2\.5;

Outcomes

Primary Outcomes

Not specified

Similar Trials